Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tango Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TNGX
Nasdaq
8731
https://www.tangotx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tango Therapeutics Inc
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 1st, 2024 8:48 pm
Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results
- Mar 20th, 2024 9:31 am
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
- Mar 18th, 2024 11:00 am
Tango Therapeutics to Participate in Upcoming Investor Conferences
- Mar 6th, 2024 12:00 pm
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Mar 5th, 2024 9:47 pm
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
- Mar 3rd, 2024 12:04 pm
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- Jan 31st, 2024 12:00 pm
MedivirĀ“s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
- Jan 4th, 2024 7:47 am
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
- Jan 3rd, 2024 12:00 pm
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%
- Dec 13th, 2023 10:03 am
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
- Nov 13th, 2023 12:00 pm
Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates
- Nov 8th, 2023 8:12 pm
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Nov 8th, 2023 12:00 pm
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
- Nov 7th, 2023 12:00 pm
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Sep 18th, 2023 11:00 am
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
- Sep 6th, 2023 11:00 am
Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 11:00 am
Tango Therapeutics Announces Updates to Its Board of Directors
- Aug 29th, 2023 9:08 pm
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
- Aug 28th, 2023 11:00 am
Tango Therapeutics Announces $80 million Private Placement Financing
- Aug 10th, 2023 11:00 am
Scroll